

## Addendum to:

# Patient Group Direction (PGD) for the supply of mebendazole 100 mg chewable tablets or mebendazole 100 mg / 5 mL oral suspension for the treatment of threadworm by pharmacists delivering the Common Ailments Service component of the Clinical Community Pharmacy Service [CYM-25027]

This document provides an addendum to the [Mebendazole CAS PGD v3.0 \[CYM-25027\]](#) valid from 01 November 2025 to 31 October 2028:

### Section 4. Clinical condition

**Inclusion criteria** - Mebendazole 100 mg chewable tablets or mebendazole 100 mg / 5 mL oral suspension can be supplied to individuals aged 6 months and over:

- **presenting with symptoms of threadworm OR**
- **are asymptomatic and belong to a household where threadworm has been identified.**

### Prepared by the Welsh Medicines Advice Service (WMAS)

Any queries regarding the content of this advisory document should be addressed to: [welshmedicines.information@wales.nhs.uk](mailto:welshmedicines.information@wales.nhs.uk)

The relevant amendments, governance and sign off for any PGD is the responsibility of the authorising organisation in Wales.

**Operational from:** 01 December 2025

**Expiry date:** 31 October 2028




**Review date:** 31 July 2028

**Version number:** 1.0

## Approval and ratification





This addendum is approved by the following health professionals on behalf of NHS Wales.

**This section MUST REMAIN when an addendum to a PGD is adopted by an organisation.**

Name	Designation	Signature
Main author – Dianne Burnett	Director, Welsh Medicines Advice Service. Cardiff and Vale UHB. Member of the Vaccine Clinical Advisory Group	
Professional Group reviewer – Adam Mackridge	Strategic Lead Pharmacist for Community Pharmacy, Betsi Cadwaladr UHB	
Expert reviewer – Kate Wright	Executive Medical Director, Powys Teaching Health Board	

This addendum has been approved by the Community Pharmacy Clinical Advisory Group (CPCAG).

**Date approved:** 24 November 2025

Organisational approval (legal requirement)			
Role	Name	Sign	Date
Lead Doctor for PTHB	Dr Kate Wright	 1F267952823F473...	12/16/2025
Chief Pharmacist for PTHB	Jonathan Boyd	 6D8ECFE8C9EB423...	12/17/2025
Clinical Governance Lead for PTHB	Amanda Edwards	 74A4E51A42E9473...	1/15/2026
Senior Pharmacist Lead for Community Pharmacies, PTHB	Emlyn Pritchard	 EB776BA7283F49B...	12/18/2025

**[Powys Teaching Health Board]** authorises the continued use of the Mebendazole CAS PGD v3.0 [CYM-25027] with this addendum for use by community pharmacies within its area that have been commissioned to provide the Common Ailments Service component of the Clinical Community Pharmacy Service. This authorisation is limited to those pharmacy professionals that meet the requirements set out within the PGD.



### **Additional clinical conditions or situations to which this addendum applies**

In accordance with the Mebendazole CAS PGD v3.0

WMAS publication number: CYM-25027

Section 4. Clinical condition	
<b>Inclusion criteria</b>	<p>Mebendazole 100 mg chewable tablets or mebendazole 100 mg / 5 mL oral suspension can be supplied to individuals aged 6 months* and over:</p> <ul style="list-style-type: none"> <li>➤ presenting with symptoms of threadworm <b>OR and:</b></li> <li>➤ <b>are asymptomatic AND belong to a household where threadworm has been identified.</b></li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>➤ they have no contraindications to mebendazole 100 mg chewable tablets or mebendazole 100 mg / 5 mL oral suspension – see <a href="#">SmPC</a>.</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>➤ informed consent has been given (individual, parent/guardian, carer).</li> </ul> <p><b>* Mebendazole use in children under 2 years of age is off label.</b> See <a href="#">off-label</a> section.</p>